Propranolol

證據等級: L5

預測適應症: 10 個

Propranolol: From Beta-Blocker Cardiovascular Therapy to Cardiomyopathy

One-Sentence Summary

Propranolol is a long-established non-selective beta-adrenergic blocker; this evidence pack screened it against thousands of diseases via TxGNN and returned 10 candidate new indications, most with no supporting clinical or literature evidence. The one candidate with genuine, decades-deep support is Cardiomyopathy (specifically the hypertrophic cardiomyopathy phenotype), backed by 3 clinical trials and 20 publications, including a randomized double-blind trial. The model’s single highest-scoring prediction (distal myopathy, Tateyama type) is explicitly flagged in the evidence pack itself as a likely knowledge-graph artifact rather than a real mechanistic signal — see the note below.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (drug/company-level `original_indications` and SA licence data are both empty — data gap). Propranolol is internationally recognized as a non-selective β-blocker used across hypertension, arrhythmia, and angina.
Predicted New Indication	Cardiomyopathy (hypertrophic cardiomyopathy phenotype)
TxGNN Prediction Score	99.12% (rank 4410 in full model output; rank 6 of 10 candidates in this pack)
Evidence Level	L1
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Important caveat: This drug’s numerically top-ranked TxGNN prediction is “distal myopathy, Tateyama type” (score 99.40%), not cardiomyopathy. The evidence pack’s own rationale states this connection has “no known biological relationship to propranolol’s β-adrenergic blocking mechanism” and is likely driven by knowledge-graph proximity to the general “myopathy” category rather than real mechanistic evidence (Evidence Level L5, decision stage S0, recommendation: Hold). We lead this report with cardiomyopathy instead because it is the only candidate with substantive trial and literature support — see the full ranking table below.

Why is This Prediction Reasonable?

Detailed formal MOA data for propranolol is not present in this evidence pack (data gap). Based on the drug-level evidence that is available, propranolol is a non-selective β1/β2-adrenergic receptor antagonist. Its negative inotropic and negative chronotropic effects reduce myocardial contractility, heart rate, and myocardial oxygen consumption, and in obstructive cardiomyopathy this reduces the left ventricular outflow tract (LVOT) pressure gradient.

This mechanism is not a novel hypothesis — propranolol has been used empirically in hypertrophic cardiomyopathy (HCM) since at least the early 1970s, and the literature evidence below includes a randomized double-blind trial from 1973 through hemodynamic studies spanning five decades. The relationship between propranolol’s original cardiovascular pharmacology and the cardiomyopathy indication is therefore direct and mechanistically explicit, rather than an extrapolation across unrelated organ systems.

By contrast, several of the other candidates flagged by TxGNN in this pack (distal myopathy, congenital myopathy with excess thin filaments, chondroma) involve structural/genetic pathologies (sarcomere protein defects, cartilage neoplasia) with no known connection to β-adrenergic blockade, and carry zero clinical trial or literature support — these are explicitly marked as Hold/S0 in the source rationale.

Overview of All Predicted Indications (This Pack)

Rank	Predicted Indication	TxGNN Score	Evidence Level	Decision Stage	Recommendation
1	Distal myopathy, Tateyama type	99.40%	L5	S0	Hold
2	Congenital myopathy with excess of thin filaments	99.30%	L5	S0	Hold
3	Hypertrophic cardiomyopathy due to intensive athletic training	99.17%	L4	S1	Research Question
4	Chondroma	99.14%	L5	S0	Hold
5	Cirrhotic cardiomyopathy	99.12%	L3	S2	Research Question
6	Cardiomyopathy (featured above)	99.12%	L1	S3	Proceed with Guardrails
7	Intramuscular hemangioma	98.97%	L2	S2	Proceed with Guardrails
8	Maffucci syndrome	98.97%	L4	S1	Research Question
9	Breast epithelioid hemangioma	98.91%	L3	S2	Research Question
10	Breast capillary hemangioma	98.90%	L2	S3	Proceed with Guardrails

Clinical Trial Evidence — Cardiomyopathy

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04767061	Phase 4	Completed	9	N-of-1 trials of beta-blocker deprescribing in HFpEF (a cardiomyopathy phenotype); directly relevant, completed, but very small sample.
NCT05019027	Phase 4	Enrolling by invitation	20	N-of-1 deprescribing trials in older adults with transthyretin cardiac amyloidosis; indirectly relevant to beta-blocker use in cardiomyopathy populations.
NCT05427474	Phase 3	Unknown	90	Propranolol + gabapentin for paroxysmal sympathetic hyperactivity after traumatic brain injury; supports autonomic-modulating role, not a cardiomyopathy efficacy trial.

Literature Evidence — Cardiomyopathy

PMID	Year	Type	Journal	Key Findings
4586631	1973	RCT	British Heart Journal	Double-blind trial of propranolol vs. practolol in hypertrophic cardiomyopathy.
7200796	1982	Cohort	British Heart Journal	Combined nifedipine + propranolol superior to nifedipine alone for hemodynamics in hypertrophic obstructive cardiomyopathy (HOCM).
1611637	1992	Cohort	Cardiology	Propranolol and disopyramide effects on LV function at rest/exercise in HCM.
7192151	1980	Cohort	British Heart Journal	Propranolol effects on myocardial oxygen consumption and hemodynamics in HOCM.
6686544	1983	Cohort	European Heart Journal	Propranolol vs. verapamil effects on diastolic stiffness in HCM.
3673167	1987	Cohort	Zeitschrift für Kardiologie	Combined nifedipine + propranolol treatment in HCM over 6–24 months.
8989641	1996	Cohort	Journal of Cardiac Failure	Hemodynamic predictors of propranolol tolerance and long-term effects in dilated cardiomyopathy.
3189143	1988	Cohort	American Heart Journal	Acute hemodynamic effects of pindolol vs. propranolol in dilated cardiomyopathy.
36104228	2022	Case Report	International Heart Journal	Infantile mitochondrial cardiomyopathy with LVOT stenosis treated with low-dose propranolol + cibenzoline.
10460081	1999	Case Report	Pediatric Emergency Care	Acute dilated cardiomyopathy and CNS toxicity following propranolol overdose — safety signal relevant to dosing.

Other Predicted Indications (Condensed)

Breast capillary hemangioma (L2, Proceed with Guardrails) — Supported by NCT04105517 (completed post-marketing surveillance of Hemangiol®/oral propranolol, n=500, in proliferative infantile hemangioma) and NCT02732678 (Phase 1/2, propranolol + cyclophosphamide in angiosarcoma, status unknown). One supporting meta-analysis: PMID 32647928 (beta-antagonist + laser combination therapy for infantile hemangioma). Propranolol (as Hemangiol®) is an internationally approved therapy for infantile hemangioma; breast location is an anatomical subtype, not a distinct disease.

Intramuscular hemangioma (L2, Proceed with Guardrails) — No dedicated trials, but supported by a randomized double-blind trial of topical propranolol gel (PMID 34719577) and multiple cohort studies of infantile hemangioma at deep/subglottic sites (PMID 35512856, PMID 35988523). Mechanistic extrapolation from established infantile hemangioma indication; no intramuscular-subtype-specific trial registered.

Cirrhotic cardiomyopathy (L3, Research Question) — Propranolol is already standard therapy for variceal bleeding prophylaxis in cirrhosis. Evidence is mixed: PMID 38738176 reports correction of prolonged QTc, while PMID 32446716 reports non-selective beta-blockers can impair circulatory homeostasis and renal function in refractory ascites — a genuine safety trade-off requiring caution.

Breast epithelioid hemangioma (L3, Research Question) — 8 literature citations, predominantly cohort/case reports on infantile hemangioma of the breast generally (PMID 38196847, PMID 20615772); no subtype-specific controlled trials.

Hypertrophic cardiomyopathy due to intensive athletic training (L4, Research Question) — Mechanistically plausible extension of the standard HCM rationale, but this athlete-specific subtype has distinct exercise-induced remodeling pathophysiology, competitive-eligibility implications, and zero direct trials or literature.

Maffucci syndrome (L4, Research Question) — Mechanistic extrapolation from the hemangioma indication only; the syndrome also involves non-vascular chondroma components. No direct evidence.

Distal myopathy (Tateyama type), congenital myopathy with excess thin filaments, chondroma (all L5, Hold) — No clinical trials, no literature, and the evidence pack’s own rationale states these connections lack biological plausibility relative to propranolol’s known pharmacology.

South Africa Market Information

No SAHPRA registrations are recorded in this evidence pack (total_licenses: 0, market status: Not Marketed). No approved indication text, product name, or dosage form data is therefore available for this jurisdiction.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for the Cardiomyopathy indication specifically; Hold for the majority of other candidates in this pack, including the model’s top-scoring prediction)

Rationale:

Cardiomyopathy (HCM phenotype) is supported by an RCT and multiple cohort studies spanning 50 years, and reflects a mechanistically direct, already-practiced use of propranolol — evidence is sufficient to proceed cautiously.
The TxGNN model’s single highest-scoring candidate (distal myopathy, Tateyama type) has no clinical or literature support and is explicitly flagged in the source rationale as likely a knowledge-graph artifact; it should not be pursued on the strength of score alone.
Breast/intramuscular hemangioma indications are reasonable secondary candidates given propranolol’s approved status for infantile hemangioma (Hemangiol®), but lack subtype-specific trials.

To proceed, the following is needed:

Formal mechanism-of-action (MOA) documentation for propranolol (currently a data gap)
TFDA/SAHPRA-approved Professional Information (PI), including warnings, contraindications, and drug interactions (currently all data gaps)
If pursuing the cirrhotic cardiomyopathy or hemangioma directions, a formal risk-benefit review given the conflicting renal/hemodynamic safety signals in cirrhosis and the pediatric population exposure profile for hemangioma indications
Local SAHPRA registration status confirmation, since this evidence pack shows zero current licenses for this jurisdiction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.